The two companies will develop digital patient monitoring for people with advanced renal cell carcinoma (RCC), using Elekta’s Kaiku Health solution, a digital platform for patient engagement and reported outcomes monitoring.

Elekta, with support from MSD, will develop a digital module for patients, keeping them connected with their care team, and educating them about their disease, the treatment and possible side effects, the company states. This module includes comprehensive symptom monitoring and patient support, providing patients with tailored and timely symptom monitoring. In addition, the module offers digital education and support materials created specifically for IO-TKI combination therapy in advanced RCC. The module will be validated in 2024 in collaboration with multiple leading cancer clinics in Europe.

Read more: Q&A: Kaiku Health – from startup to acquisition

“Addressing potential challenges in cancer care involves the implementation of digital patient support. With support of MSD, our shared objective is to improve communication between patients and their care teams. This initiative aims to provide structured support for symptom management and monitoring while also educating patients about their disease and treatment,” says Anish Patankar, SVP & Head of Business Line Software at Elekta.

Photo: iStock